You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
Liphorus Pharmaceuticals Inc.
Headquarters:Montreal, Canada
Year Founded:2014
Historical deals and financings can be found by searching the organization's name in the BCIQ Deals and Financing Modules*.*desktop version only

BioCentury | Apr 20, 2017

Product R&D

Stalling translation

...of PCSK9 in preclinical development that were out-licensed to an undisclosed company last year, and Liphorus Pharmaceuticals Inc....
...NASDAQ:AMGN), Thousand Oaks, Calif. Arrakis Therapeutics Inc., Waltham, Mass. Genentech Inc., South San Francisco, Calif. Liphorus Pharmaceuticals Inc....

BioCentury | Oct 05, 2015

Emerging Company Profile

Picking a PCSK9

...are making their market debuts, several companies are vying to replace them with oral candidates. Liphorus Pharmaceuticals Inc....
...Genentech Inc., South San Francisco, Calif. Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec Liphorus Pharmaceuticals Inc....
..."Nurturing killer seeds." BioCentury (2014) Martz, L. "PCSK9 peptide inhibitors." SciBX: Science-Business eXchange (2014) Sidebars Liphorus Pharmaceuticals Inc....

BioCentury | Sep 21, 2015

Product Development

Alnylam's lipid sync

...ALN-PCSsc's dosing also could improve adherence over oral approaches to inhibiting PCSK9. Pfizer Inc. , Liphorus Pharmaceuticals Inc....
...Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. European Society of Cardiology (ESC), Sophia Antipolis, France Liphorus Pharmaceuticals Inc....

BioCentury | Nov 10, 2014

Company News

IRCM, Liphorus Pharmaceuticals deal terms are not disclosed. Institut de Recherches Cliniques de Montreal (IRCM) , Montreal, Quebec Liphorus Pharmaceuticals Inc....

BioCentury | Nov 07, 2014

Financial News

Sanderling backs IRCM spinout Liphorus

Liphorus Pharmaceuticals Inc. (Montreal, Quebec) raised $6.4 million in a series A round from Sanderling Ventures. The startup plans to develop small molecules targeting proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) to treat hypercholesterolemia. The company...